-The Times of India The report of the comptroller and auditor general (CAG) on the Delhi government for the year ended March 2012 is a scathing indictment of many departments and public utilities. Healthcare, transport, power, water and sewage and even showcase infrastructure projects and schemes have been put under the lens and the picture that has emerged is not all that pretty. The report was tabled in the Delhi assembly...
More »SEARCH RESULT
Food as a right
-The Hindu In its latest form, the National Food Security Bill, 2013 promises to address the extreme irony of an ambitious nation holding mountains of food in storage, while masses of its people are undernourished or even starving. The right to food is finally on the threshold of being legislated. Every step taken to widen the coverage of food security schemes is an advance. Yet, the empirical truth is that...
More »Supreme Court rules for cheap cancer drug -Subodh Varma
-The Times of India The Supreme Court on Monday rejected pharma giant Novartis AG's plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection...
More »Supreme Court's Glivec ruling will ruin innovation
-The Economic Times Extension of life is priceless. Simply priceless." These were the words of Venkat Krishnan (name changed) to Novartis after receiving treatment with Glivec for about two years. Following his diagnosis with chronic myeloid leukaemia (CML), Venkat married his college sweetheart against the wishes of her family. After all, the prognosis in those days for people suffering from CML was not promising. Taking interferon, a powerful immune therapy, was the...
More »Novartis order may force pharma MNCs to change
-The Economic Times Foreign pharma companies could be forced to overhaul their strategy for the Indian market by striking more local deals and cutting sky-high drug prices after the Supreme Court slammed the door on Swiss giant Novartis' attempts to gain a patent for its blood cancer-busting drug Glivec. But the ruling, welcomed by activists campaigning for affordable drugs and local generic companies, threatened to reinforce a narrative that India...
More »